Using Shuttle technology, the Feldan team and their collaborators, including teams from TransBIOTech, have succeeded in demonstrating for the first time the feasibility of base editing in the lungs of non-human primates. This study provides anin vivo proof of concept of functional delivery to lung cells in this model, and highlights the therapeutic potential of Feldan Shuttle as a delivery agent to lung cells and the development of treatments for lung diseases. Feldan thanks its collaborators at the University of Iowa, UC Davis, Johns Hopkins University School of Medicine, Harvard University, Integrated DNA Technologies and TransBIOTech for this achievement.
Read the article here: https://www.nature.com/articles/s41467-023-43904-w
